These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12707578)

  • 21. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature.
    Chen DY; Lau CS; Elzorkany B; Hsu PN; Praprotnik S; Vasilescu R; Marshall L; Llamado L
    Int J Rheum Dis; 2018 Feb; 21(2):362-372. PubMed ID: 29205904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis.
    Didden EM; Ruffieux Y; Hummel N; Efthimiou O; Reichenbach S; Gsteiger S; Finckh A; Fletcher C; Salanti G; Egger M;
    Med Decis Making; 2018 Aug; 38(6):719-729. PubMed ID: 30074882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
    Jones G; Hall S; Bird P; Littlejohn G; Tymms K; Youssef P; Chung E; Barrett R; Button P
    Int J Rheum Dis; 2018 Aug; 21(8):1581-1590. PubMed ID: 29205926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treat-to-target biologic therapy in patients with rheumatoid arthritis is more efficacious and safe compared to delayed initiation of biologics: a real-world study.
    Lampropoulos CE; Orfanos P; Manoussakis MN; Tzioufas AG; Moutsopoulos HM; Vlachoyiannopoulos PG
    Clin Exp Rheumatol; 2017; 35(2):192-200. PubMed ID: 28094760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Rheumatoid arthritis plus osteoporosis. How much corticoid will this patient still tolerate?].
    Fassbender WJ
    MMW Fortschr Med; 2012 Feb; 154(3):34. PubMed ID: 22458166
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New role for an old friend: prednisone is a disease-modifying agent in early rheumatoid arthritis.
    Conn DL; Lim SS
    Curr Opin Rheumatol; 2003 May; 15(3):193-6. PubMed ID: 12707570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept.
    Peper SM; Lew R; Mikuls T; Brophy M; Rybin D; Wu H; O'Dell J
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1467-1472. PubMed ID: 28388820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis.
    Ruderman EM
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S29-32. PubMed ID: 24219038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologic Therapies for Rheumatologic and Autoimmune Conditions.
    Bays AM; Gardner G
    Med Clin North Am; 2016 Jul; 100(4):719-31. PubMed ID: 27235612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of rheumatoid arthritis: Unraveling the conundrum.
    Zampeli E; Vlachoyiannopoulos PG; Tzioufas AG
    J Autoimmun; 2015 Dec; 65():1-18. PubMed ID: 26515757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Glucocorticoids].
    Gromnica-Ihle E
    Z Rheumatol; 2016 Aug; 75(6):591-4. PubMed ID: 27412667
    [No Abstract]   [Full Text] [Related]  

  • 35. The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.
    Feuchtenberger M; Kleinert S; Scharbatke EC; Gnann H; Behrens F; Wittig BM; Greger G; Tony HP
    Clin Exp Rheumatol; 2015; 33(3):321-9. PubMed ID: 25897681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression.
    Hosoya T; Iwai H; Yamaguchi Y; Kawahata K; Miyasaka N; Kohsaka H
    Ann Rheum Dis; 2016 Jan; 75(1):253-9. PubMed ID: 25165034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-cell agents in the treatment of rheumatoid arthritis.
    Solomon GE
    Bull NYU Hosp Jt Dis; 2010; 68(3):162-5. PubMed ID: 20969545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Biologics].
    Kalden JR
    Z Rheumatol; 2016 Aug; 75(6):604-10. PubMed ID: 27365024
    [No Abstract]   [Full Text] [Related]  

  • 40. Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients.
    Mori S; Yoshitama T; Ueki Y
    Intern Med; 2018 Mar; 57(5):663-670. PubMed ID: 29151519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.